English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/2972
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Fructose-1,6-biphosphate in rat intestinal preconditioning: involvement of nitric oxide

AuthorsSolà, Anna M. ; Roselló-Catafau, Joan ; Gelpí, Emili ; Hotter, Georgina
Glyceraldehyde- 3-phosphate dehydrogenase
Intestinal preconditioning
Ischaemia/reperfusion injury
Nitric Oxide
Issue DateFeb-2001
PublisherBMJ Publishing Group
CitationGut. 2001 February; 48(2): 168–175.
Abstract[BACKGROUND AND AIMS] Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by nitric oxide (NO) in intestinal preconditioning could modify the rate of formation of glycolytic intermediates. Fructose-1,6-biphosphate (F16BP) is a glycolytic intermediate that protects tissue from ischaemia/reperfusion injury. We evaluated if F16BP may be endogenously accumulated as a consequence of GAPDH inhibition by NO during intestinal preconditioning in rats.
[METHODS] We assessed: (1) effect of preconditioning on F16BP content; (2) effect of NO on GAPDH activity before and during sustained ischaemia; and (3) protective effect of F16BP in control, ischaemic, and preconditioned animals with or without administration of N-nitro-L-arginine methyl ester (L-NAME), NO donor, or F16BP.
[RESULTS] Preconditioned rats showed a significant transient decrease in GAPDH activity and also maintained basal F16BP levels longer than ischaemic rats. L-NAME administration to preconditioned rats reversed these effects. F16BP administration to ischaemic rats decreased protein release in the perfusate. Administration of F16BP to L-NAME treated rats attenuated the harmful effect of L-NAME.
[CONCLUSIONS] Our study indicates that F16BP may be endogenously accumulated in preconditioned rats as a consequence of inhibition of GAPDH by NO, and this may contribute to the protection observed in intestinal preconditioning.
Publisher version (URL)http://dx.doi.org/10.1136/gut.48.2.168
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
fructose.pdfText file151,04 kBAdobe PDFThumbnail
fructose_f1.jpgFigure 1.- Intestinal fructose-1,6-biphosphate (F16BP) levels during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.73,74 kBJPEGThumbnail
fructose_f2.jpgFigure 2.- Intestinal glucose levels during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.47,05 kBJPEGThumbnail
fructose_f3.jpgFigure 3.- GAPDH activity (U/mg protein) in the intestine during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.73,04 kBJPEGThumbnail
fructose_f4.jpgFigure 4.- Nitrate and nitrite tissue production in the intestine in the following groups: control, control with previous administration of L-NAME (C+NAME), preconditioning.45,75 kBJPEGThumbnail
fructose_f5.jpgFigure 5.- Profiles of protein release during the different ischaemic (0, 2, 30, and 90 minutes) and reperfusion.53,72 kBJPEGThumbnail
fructose_f6.jpgFigure 6.- Intestinal fructose-1,6-biphosphate (F16BP) levels incorporated in the intestine.19,54 kBJPEGThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.